Metastatic Prostate Cancer: Background and Patient Prognosis

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

Catch up on all the notable drug and device approvals in urology over the past year.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.